Table 1 Current therapeutic treatments and emerging therapies to cure NASH
From: Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
Current therapies | |
Lifestyle changes | Increased physical activity |
Specified dietary restrictions | |
Insulin-sensitizing agents | Metformin |
Pioglitazone | |
Antioxidant agent | α-tocopherol (vitamin E) |
Lipid-lowering drugs | Statins |
Emerging therapies | |
Anti-inflammatory and/or antifibrotic treatments | Resmetirom |
Lanifibranor | |
Firsocostat | |
Aramchol | |
PNPLA3 gene silencing | |
Semaglutide | |
Tirzepatide | |
FGF19/FGF21 analogues | |
Inhibition of HSCs activation into matrix-producing myofibroblasts | |
Treatments to reduce the immune response | Chemokine receptor inhibitors |
Galectin-3 inhibitors | |
Anti-platelet modulators | |